Pluristem

The Israeli-Emirati joint projects aim to utilize each company's strengths in order to achieve results that will integrate the expertise of both companies.

More coronavirus patients who do not qualify for the company’s clinical trial will now be able to receive treatment

The survival rate is 87.5%, Pluristem Therapeutics reported.

Six critically ill coronavirus patients in Israel who were considered high-risk for mortality were treated with Pluristem and survived.

The financing is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the financial pillar of the European Union's Investment Plan for Europe.

After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.

Not only have all the patients survived, according to Pluristem, but four of them showed improvement in respiratory parameters.

Haifa company weeks away from presenting clinical trial results that could ‘generate hope’ for patients suffering from untreatable vascular disease.

Innovative Israeli cell therapy could step up treatment of CLI.

Cancer is a leading cause of death around the world and its incidence continues to rise. Each year around 12.7 million people discover they have cancer and 7.6 million people die from it.